藥明康德(603259.SH)擬定了2020年H股獎勵信託計劃
格隆匯 7 月 21日丨藥明康德(603259.SH)公佈,公司第二屆董事會第三次會議決議,審議通過《關於審議<無錫藥明康德新藥開發股份有限公司2020年H股獎勵信託計劃(草案)>的議案》;
為了吸引、激勵和保留有豐富技能和經驗的人才,給予其享有公司股票權益的機會,以實現公司未來的發展和擴張;同時深化公司薪酬制度改革,發展並不斷完善股東、經營管理層和執行管理層之間的利益平衡機制;並肯定包括董事在內的公司領導層的貢獻,鼓勵、激勵並維持有利於公司持續經營和發展的公司領導層,以及通過將公司領導層的利益與股東和公司整體的利益一致化的方式為公司領導層提供激勵。公司根據相關法律法規並結合公司實際情況擬定了《無錫藥明康德新藥開發股份有限公司2020年H股獎勵信託計劃(草案)》,並已經董事會薪酬與考核委員會同日審議通過。同意《H股獎勵信託計劃》的相關內容。
根據《H股獎勵信託計劃》公司將與香港中央證券信託有限公司(Computershare Hong Kong Trustees Limited,“受託人”)簽署信託契約。在本計劃項下公司將向受託人提供不超過港幣7億元資金用以根據《H股獎勵信託計劃》從公開市場上收購H股股票作為本計劃項下獎勵股票的來源。公司的資金來源為自有資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.